Intravascular adenoviral agents in cancer patients: lessons from clinical trials. - Wikidata - awgldk - TriplyDB

Intravascular adenoviral agents in cancer patients: lessons from clinical trials.

Intravascular adenoviral agents in cancer patients: lessons from clinical trials.

http://www.wikidata.org/entity/Q35043094

about

Mathematical modeling of tumor therapy with oncolytic viruses: regimes with complete tumor elimination within the framework of deterministic models.Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications Going viral: a review of replication-selective oncolytic adenoviruses Adenovirus vectors for gene therapy, vaccination and cancer gene therapy RNA interference and potential therapeutic applications of short interfering RNAs Tumor-specific delivery of biologics by a novel T-cell line HOZOT.Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.Short interfering RNA (siRNA) as a novel therapeutic.Mathematical modeling of tumor therapy with oncolytic viruses: effects of parametric heterogeneity on cell dynamics.Directed evolution generates a novel oncolytic virus for the treatment of colon cancer Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factor Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus Evaluation of adenovirus capsid labeling versus transgene expression Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus Cancer-induced expansion and activation of CD11b+ Gr-1+ cells predispose mice to adenoviral-triggered anaphylactoid-type reactions Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo.Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging.Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth.Replication and virus-induced transcriptome of HAdV-5 in normal host cells versus cancer cells--differences of relevance for adenoviral oncolysis.Viral and nonviral delivery systems for gene delivery Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial.Mutation of the fiber shaft heparan sulphate binding site of a 5/3 chimeric adenovirus reduces liver tropism.Gene therapy for cancer treatment: past, present and future Methods for screening tumors for p53 status and therapeutic exploitation.Progress and perspectives in chemoprevention of head and neck cancer.Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs.Gene Therapies for Cancer: Strategies, Challenges and Successes.Increasing the efficacy of oncolytic adenovirus vectors Parvovirus vectors for cancer gene therapy.Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases.Gene therapy in orthopaedic surgery: the current status.Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer Therapeutic efficacy of paclitaxel and carboplatin via arterial or venous perfusion in rabbits with VX-2 tongue cancer.Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host.An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies.Adenovirus as vehicle for anticancer genetic immunotherapy.

P2860

Q25257260-60A46DA6-E7FD-431E-A2A1-CA3F92CFE848 Q26776553-C22CCE75-1209-4973-81AA-CC64E5D52050 Q26797520-D6C6045F-A60C-4477-8AB1-30D14E5900B0 Q27001601-0DE2D3FB-7918-40A5-B758-5C796BCEE58C Q28250480-EFDE7035-F052-417E-AC4A-C9E5BA9FB015 Q30830225-247D1C41-3749-413C-9BF3-09C9E2283E64 Q33221159-B1BDBEAA-9DB9-44FE-A79C-04A8557317E9 Q33243420-ABDAC96A-29FC-4D01-B729-AE0634E9B9C9 Q33259239-FF31AB03-8633-42BB-A10C-E325DDADA43A Q33344440-1C74FEB8-034D-4EA6-A1D7-583EC242D9A7 Q33387265-77666EFA-E453-403E-A5FB-1107E0CB333F Q33622711-83BC41BC-DFFD-4A0D-8596-3DE2EE63FFCD Q33633287-1124FD46-9AEB-46BE-9F33-4F2C07BC73B2 Q33669272-D2CFA274-5E0B-4339-82B0-D7A050AF8F4A Q33690982-9D4BC076-F702-4FC3-91A2-6961A7505C15 Q33713324-F781A27C-BC96-402B-A652-C068930B7F3D Q33771285-7E7C049F-D55C-45CD-A483-9902D5BB4859 Q33803963-0F6C6CDE-CBC3-4ED0-8265-A62BE256C187 Q34025129-39E3C837-D262-4D10-9287-17DE8F48F935 Q34091152-F03B75FB-F632-46B0-A7E9-E20D52E03725 Q34315475-4B26ACA7-D7F6-40E7-9B5B-8C1F1F188AC9 Q34659341-3A2905E2-AE64-44B3-9D18-441876539042 Q34667746-9CD3CE97-BD88-4708-9781-648A5DB26664 Q35040146-DCA5094A-9FA1-4D38-808E-D4ECD8BE4040 Q35142162-5913288D-02AF-461A-9F38-70AD4849ABAB Q35160205-CA951B0C-E51C-45B1-8780-C605463572CD Q35174932-0BA7BE9A-1868-4242-AC29-810F9E630B2A Q35186312-BC37A39B-57AB-4999-AD35-60D9693756C6 Q35261325-1DFC4A98-57AD-4AF5-B922-59820B854562 Q35609780-3C656733-288C-4B24-8BEA-B2B7D0074AD1 Q35618835-FC006860-2E00-4EC1-989D-109282997B45 Q35630146-3187BAC7-5512-4ABC-8431-F643B12466F1 Q35665175-B7CC5045-1974-48A1-8452-8B79DBD2AF28 Q35791394-20640F39-C2DF-434B-B615-C0D2C0FFE78F Q36065853-92B2FD5A-4526-4DC6-A445-FD20BA3E6ECB Q36179390-A6A49EB4-25A2-4782-9408-97FAE4B26855 Q36209165-EB45ACC2-5174-4D72-90EE-FAD4A50E3B60 Q36209172-C46C4C47-5E12-4749-9F54-F54552C7EA86 Q36258513-77DD42C0-3879-4F5C-847E-51631AF378D7 Q36288930-F8CE5761-3342-4929-81A9-7CB0363F53B3

P2860

Intravascular adenoviral agents in cancer patients: lessons from clinical trials.

http://www.wikidata.org/entity/Q35043094

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Intravascular adenoviral agents in cancer patients: lessons from clinical trials.

@en

type

label

Intravascular adenoviral agents in cancer patients: lessons from clinical trials.

@en

prefLabel

Intravascular adenoviral agents in cancer patients: lessons from clinical trials.

@en

P1433

Q35043094-6D3904DB-8681-4BFB-B255-B10450E979A4

P1476

Q35043094-6E041504-39CC-4564-B08C-39D211B8A58F

P2093

Q35043094-7B8C800C-4954-4261-AE0A-3B5EC8BC287D

Q35043094-7DAAC2B3-7886-4493-BBDB-D8BCC1DDB227

Q35043094-BADFAFB4-F5EB-45E7-9638-325EE848FFB8

P2860

Q35043094-024525C5-D487-4359-AAD2-73BC67F4E852

Q35043094-175E4BB1-D503-4B43-AA66-DBAA2652DEBE

Q35043094-213BA4E2-B701-43B2-B0B9-9457FD35D854

Q35043094-2924851E-9CAF-4090-9A3C-210556BDB47C

Q35043094-3DE3FD77-B03B-4F3A-9F14-55BCE232BAE0

Q35043094-42240293-B7F6-4A49-BB11-89EBA8D06DE8

Q35043094-437A9544-7C0C-4280-8570-FB623137FA68

Q35043094-437B0296-789B-4DFC-90D7-33AD1B36AA43

Q35043094-53902A8C-F6B2-43AA-AFFD-24B43BF9C1C4

Q35043094-5D1ACE49-DE34-4F8E-9A07-80A4279AE8EF

P2888

Q35043094-05BEE2B8-BC0F-4ADC-BBC2-29130AC40FF3

P304

Q35043094-DAF2F6BE-BDCF-40A8-8EA4-72A54071AFF5

P31

Q35043094-F2E60272-B2DA-47E1-9459-4405DF11EED2

P356

Q35043094-ECA27EB8-E9FF-48CE-8DBC-90E50A515434

P433

Q35043094-03359C3A-F075-4FBD-9634-06A64549C14E

P478

Q35043094-C14D0A9C-5302-41A7-BF3F-5D2F8E8F2BDF

P577

Q35043094-BF8E5D1C-38BA-47E0-B9C1-581FAC999AEB

P5875

Q35043094-29F74295-1E84-41AF-B807-28D1B67B0904

P698

Q35043094-814F1585-48E6-4DB5-8FCA-FC3D7C7A536B

P921

Q35043094-B8FD496E-5DF9-43A2-ACB7-3329DC32C6E7

P356

P1433

Cancer Gene Therapy

P1476

Intravascular adenoviral agents in cancer patients: lessons from clinical trials.

@en

P2093

David Kirn

http://www.w3.org/2001/XMLSchema#string

Robert Warren

http://www.w3.org/2001/XMLSchema#string

Tony Reid

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein

Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer.

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas.

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

Reovirus therapy of tumors with activated Ras pathway.

Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection.

Cancer gene therapy: fringe or cutting edge?

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

P2888

P304

979-986

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.CGT.7700539

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10956357

http://www.w3.org/2001/XMLSchema#string

P698

12522437

http://www.w3.org/2001/XMLSchema#string

P921